Skip to main content
Premium Trial:

Request an Annual Quote

Salomon Initiates Coverage of Genaissance with Buy Recommendation

NEW YORK, Sept 8 – Salomon Smith Barney initiated coverage of Genaissance Pharmaceuticals (Nasdaq: GNSC) with a Venture, Buy rating and issued a 12-month price target of $32 a share.

 

Genaissance of New Haven, Conn., was trading up 1 1/16, or 4.8 percent, at $23 in late morning trading.

 

In a report, analyst Meirav Chovav said that the company has shown that its HAP technology platform for identifying gene-specific SNPs can successfully predict a person’s response to a drug or their predisposition to a disease.

 

“Genaissance has recently shown proof of principal by conducting its own genomic clinical studies on high cholesterol and asthmatic patients,” Chovav wrote. “The results from these clinical studies demonstrate that the haplotype of a patient can affect drug response and, moreover, that HAP markers have greater predictive values than individual SNPs.”

 

Results from the asthma study will be published in a peer reviewed scientific journal, she wrote.

 

The company plans to generate revenues by charging subscription and fee-for-service dues for its HAP2000 technology. Mednostics The company will also make money through licensing, milestone and royalty payments on intellectual property it generates on HAP markers.

 

Chovav said she expects Genaissance to announce two partnership deals in 2001 for its HAP2000 technology.

 

She estimated losses per share of $2.59 for full-year 2000 and $3.16 for full-year 2001. For 2002, Chovav said she expects the company’s losses to drop to $1.73 a share. Genaissance lost $2.22 a share in 1999.

 

The company’s main competitors include CuraGen (Nasdaq: CRGN), decode Genetics (Nasdaq: DCGN) and Variagenics (Nasdaq: VGNX).

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.